Myriad Genetics Stock Price, News & Analysis

Myriad Genetics (NASDAQ: MYGN) has announced the promotion of Ben Wheeler to Chief Financial Officer, effective August 16, 2025. Wheeler, a 13-year company veteran, previously served as chief financial officer of operations and has held various leadership roles since joining in 2011.

The appointment follows Scott Leffler's transition to a consulting role through September 2, 2025. CEO Sam Raha expressed confidence in Wheeler's ability to execute the company's profitable growth strategy. The company has also reaffirmed its full-year 2025 financial guidance as previously announced on August 5, 2025.

Myriad Genetics (NASDAQ: MYGN) has released findings from its Cancer Risk Survey revealing important insights about women's attitudes toward health screenings. The survey found that while 80% of women fear screenings, 75% would find genetic testing reassuring when facing health concerns.

The study highlighted that 37% of women believe genetic testing can help manage breast health, but 40% were unaware of genetic testing tools for breast cancer risk assessment. Only 14% of respondents have undergone genetic testing, despite over 25% of women in OB/GYN settings meeting hereditary cancer testing criteria.

The survey also revealed that while 50% of respondents consider parental health history important, only 30% knew their parents' health history well. Myriad's MyRisk® Hereditary Cancer Test with RiskScore® combines genetic insights, family history, and clinical factors to calculate breast cancer risk.

Myriad Genetics (NASDAQ:MYGN) reported Q2 2025 revenue of $213.1 million, up 1% year-over-year, and raised its 2025 revenue guidance to $818-828 million. The company's hereditary cancer testing showed strong performance with 9% revenue growth and 10% volume growth in Oncology.

Q2 2025 highlights include improved gross margin of 71.2% (up 160 basis points YoY) and a GAAP net loss of $330.5 million ($3.57 per share), primarily due to non-cash impairment charges of $316.7 million. The company secured a new $200 million credit facility to enhance financial flexibility.

Myriad announced a strategic shift focusing on three pillars: accelerating growth in Cancer Care Continuum, maintaining growth in Prenatal and Mental Health, and driving sustained profitable growth. The company plans to launch its proprietary MRD test in H1 2026 and expects high single to low double-digit revenue growth over the next five years.

Myriad Genetics (NASDAQ: MYGN) has secured a new $200 million credit facility from OrbiMed, a leading healthcare investment firm. The five-year senior secured term loan includes $125 million in immediate funded capital and an option for an additional $75 million available until June 30, 2027.

The facility matures on July 31, 2030, with an interest rate based on one-month SOFR plus 6.50% annually (SOFR floor of 2.50%). This new arrangement replaces Myriad's previous ABL facility and is secured by substantially all company assets. The funding strengthens Myriad's capital position, providing over $200 million in accessible capital to support its growth strategy.

Myriad Genetics (NASDAQ: MYGN), a molecular diagnostic testing and precision medicine company, has scheduled its second quarter 2025 earnings release and conference call for August 5, 2025. The financial results will be released after market close, followed by a conference call at 4:30 PM ET.

Management will discuss the company's Q2 2025 financial performance and provide a business update during the call. Investors can access the live webcast through Myriad's Investor Relations website, while those preferring telephone participation must register to receive dial-in details.

Myriad Genetics (NASDAQ: MYGN) has achieved Great Place to Work Certification for the third consecutive year, with 84% of employees endorsing the company as a great workplace - surpassing the U.S. company average by 30 percentage points.

The certification, granted by Great Place To Work®, the global authority on workplace culture, recognizes Myriad's commitment to creating an inclusive and supportive work environment. The company's success is attributed to its focus on employee resource groups, community building, and ensuring teammates feel connected and empowered.

Myriad Genetics (NASDAQ: MYGN) has announced early access to its FirstGene Multiple Prenatal Screen, a comprehensive prenatal genetic testing solution. The test combines multiple screening modalities into a single blood draw, eliminating the need for paternal testing. FirstGene will be launched through the CONNECTOR study, targeting over 5,000 patients across multiple clinical sites. The screen offers high accuracy with 98.6% sensitivity and 99.6% specificity, capable of identifying carrier status, fetal genetic anomalies, chromosomal aneuploidies, 22q11.2 microdeletion, pathogenic mutations in 10 recessive conditions, and RhD compatibility. This streamlined approach makes guideline-driven testing more accessible while representing a significant growth opportunity for Myriad in the prenatal testing market.

Myriad Genetics (MYGN) revealed promising clinical data from the MONSTAR-SCREEN-3 study for their Precise MRD Test, demonstrating 100% detection of circulating tumor DNA (ctDNA) at baseline across multiple cancer types. The study, conducted with Japan's National Cancer Center Hospital East, showed the test can detect tumor fractions as low as 0.0001% and successfully created personalized whole-genome sequencing panels for 97.3% of patients. Notably, 60% of ctDNA-positive patients one month post-surgery had ultra-low tumor fractions only detectable by Precise MRD's enhanced sensitivity. These patients showed significantly worse disease-free survival compared to ctDNA-negative patients. The test also demonstrated ability to predict pathological complete response during neoadjuvant chemotherapy and showed earlier recurrence detection compared to imaging.

Myriad Genetics (NASDAQ: MYGN) will present seven new research studies at the 2025 ASCO Annual Meeting, showcasing advancements in oncology and precision medicine. Key highlights include the MONSTAR-SCREEN-3 study, demonstrating successful pan-cancer implementation of whole genome sequencing-based personalized ctDNA detection, achieving 100% baseline detection across tumor types. The company announced upcoming product innovations including: Precise MRD Test (commercial launch in 2026), Prolaris Prostate Cancer Test with PATHOMIQ AI technology (early 2026), expanded MyRisk Hereditary Cancer Test panel (late 2025), and full EMR integration with Flatiron's OncoEMR and Epic platforms (late 2025). These developments reflect Myriad's commitment to advancing personalized cancer care through genetic and tumor genomic testing solutions.